Author

Philippe Slos

Boehringer Ingelheim (Germany)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Alan A. MelcheriD· 1 shared Anne B. VogtiD· 1 shared Anton PatrikeeviD· 1 shared Antonio RullaniD· 1 shared Charleen Chan Wah HakiD· 1 shared Christian MandliD· 1 shared Elizabeth S. AppletoniD· 1 shared Emmanuel Christian PatiniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alan A. MelcherORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes antitumour immunity in combination with radiotherapy

Malin Pedersen, Lisa C. Hubbard, Shane Foo, Anton Patrikeev, Antonio Rullan, Holly Baldock, Christian Mandl, Paolo Chetta, Jehanne Hassan, Isaac Dean, Naomi Guppy, Philippe Slos, Charleen Chan Wah Hak, Elizabeth S. Appleton, Emmanuel Christian Patin, , Kevin J Harrington

This study evaluates a second-generation STING agonist, BI-1703880, showing that combining it with radiotherapy enhances antitumour immunity and immune memory.

bioRxiv · Mar 25, 2026 · PreprintCancer Biology